Articles from Handa Pharma, Inc.

Handa Oncology Receives FDA Tentative Approval for OMCAZIO (cabozantinib) Capsules
A novel 505(b)(2) alternate-salt formulation of cabozantinib designed to improve absorption, with no clinically significant food effect
By Handa Pharma, Inc. · Via ACCESS Newswire · July 31, 2026
Articles from Handa Pharma, Inc. | WAOW